TG Therapeutics Inc.

(NASDAQ: TGTX) Trade

By |

Equities News

Company chart and information is provided by TradingView based on 15-minute-delayed data.


Profile

TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a unique epitope on the CD20 antigen found on mature B-lymphocytes. It is also developing TGR-1202 (umbralisib), an orally available PI3K delta inhibitor.

Contact Information

Website: www.tgtherapeutics.com
Email: ir@tgtxinc.com
Main Phone: +1 212 554-4484
Address: 2 Gansevoort Street
Address 2: 9th Floor
State: NY
City / Town: New York
Country: US
Postal Code: 10014

Issuer Information

Exchange: NSC
CEO: Michael S. Weiss
Employees: 272
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

View More
(%)
Company data no longer available
Last Price N/A Change $ N/A Change % N/A Tick N/A
Bid N/A Bid Size N/A Ask N/A Ask Size N/A
Open N/A High N/A Low N/A Prev Close N/A
Last Trade Volume N/A 52 Wk Hi N/A 52 Wk Low N/A
Market Cap N/A Ex-Div Date N/A Div Rate N/A Yield N/A
Shares N/A EPS (TTM) N/A PE Ratio N/A Exchange N/A